Physician profile
Eve Summers
NPI 1124493127
$4,873.68
in general payments reported to CMS, 2019-2025
25 companies · $1,494 in 2025
The $1,494 reported for 2025 was more than what 98% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $542 · 2022: $749 · 2023: $902 · 2024: $1,186 · 2025: $1,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,581.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $796.81 | 2021-2025 | |
| Rhythm Pharmaceuticals, INC. | $663.20 | 2022-2025 | Imcivree, Imcivree |
| Tolmar Pharmaceuticals, INC. | $497.89 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $430.63 | 2023-2025 | |
| Novo Nordisk INC | $429.67 | 2021-2025 | Wegovy, Sogroya |
| Ascendis Pharma Endocrinology INC | $296.73 | 2022-2025 | Skytrofa |
| Merck Sharp & Dohme LLC | $293.37 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Tolmar, INC. | $260.37 | 2023-2025 | Fensolvi |
| Glaxosmithkline, LLC. | $215.22 | 2022-2025 | Bexsero |
| Alexion Pharmaceuticals, INC. | $183.38 | 2021-2024 | Strensiq |
| Cranial Technologies, INC | $161.11 | 2023-2025 | Doc Band |
| Biomarin Pharmaceutical INC. | $112.08 | 2021-2024 | Voxzogo 1.2mg |
| Kyowa Kirin, INC. | $97.10 | 2023-2025 | Crysvita |
| Sobi, INC | $58.18 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $57.68 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $56.85 | 2023-2025 | |
| Phadia US INC. | $53.32 | 2023-2025 | Immunocap |
| Azurity Pharmaceuticals, INC. | $44.58 | 2022-2025 | Triptodur |
| Eton Pharmaceuticals, INC. | $36.09 | 2023-2025 | Alkindi, Khindivi, Increlex |
| Soleno Therapeutics, INC. | $28.89 | 2025 | Vykat Xr |
| Neurocrine Biosciences, INC. | $26.06 | 2025 | |
| Dexcom, INC. | $22.10 | 2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $21.76 | 2022 | |
| Pfizer INC. | $16.63 | 2021 | |
| Abbott Laboratories | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eve Summers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.